CATALYST PHARMACEUTICALS INC's ticker is CPRX and the CUSIP is 14888U101. A total of 133 filers reported holding CATALYST PHARMACEUTICALS INC in Q4 2019. The put-call ratio across all filers is 3.40 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $1,018 | -13.0% | 87,097 | 0.0% | 0.06% | -6.8% |
Q2 2023 | $1,170 | -1.0% | 87,097 | +22.1% | 0.06% | +11.3% |
Q1 2023 | $1,182 | -11.0% | 71,327 | -0.1% | 0.05% | -17.2% |
Q4 2022 | $1,328 | -99.9% | 71,400 | -1.4% | 0.06% | +42.2% |
Q3 2022 | $929,000 | +83.2% | 72,400 | 0.0% | 0.04% | +104.5% |
Q2 2022 | $507,000 | -15.6% | 72,400 | 0.0% | 0.02% | -8.3% |
Q1 2022 | $601,000 | -5.2% | 72,400 | -47.3% | 0.02% | +9.1% |
Q1 2021 | $634,000 | +46.1% | 137,400 | +5.9% | 0.02% | +46.7% |
Q4 2020 | $434,000 | +11.0% | 129,800 | -1.4% | 0.02% | +15.4% |
Q3 2020 | $391,000 | -39.4% | 131,600 | -5.7% | 0.01% | -27.8% |
Q2 2020 | $645,000 | +13.4% | 139,600 | -5.5% | 0.02% | +5.9% |
Q1 2020 | $569,000 | -3.2% | 147,700 | -5.9% | 0.02% | +30.8% |
Q4 2019 | $588,000 | -30.2% | 157,000 | -1.1% | 0.01% | -31.6% |
Q3 2019 | $843,000 | +38.2% | 158,700 | 0.0% | 0.02% | +35.7% |
Q2 2019 | $610,000 | – | 158,700 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
TANAKA CAPITAL MANAGEMENT INC | 148,281 | $1,902,000 | 5.68% |
GABLES CAPITAL MANAGEMENT INC. | 433,814 | $5,566,000 | 4.46% |
Quantedge Capital Pte Ltd | 503,700 | $6,462,000 | 1.99% |
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 4,896,000 | $62,816,000 | 1.25% |
Lanham O'Dell & Company, Inc. | 20,145 | $258,000 | 0.92% |
Capital Impact Advisors, LLC | 59,301 | $907,000 | 0.90% |
SummerHaven Investment Management, LLC | 98,840 | $1,268,000 | 0.88% |
Yorktown Management & Research Co Inc | 50,000 | $642,000 | 0.83% |
GLOBEFLEX CAPITAL L P | 304,293 | $3,904,000 | 0.67% |
AFFINITY INVESTMENT ADVISORS, LLC | 90,864 | $1,166,000 | 0.60% |